MedX Health Corp. Announces Closing of First Tranche of Private Placement

MedX Health Corp. ("MedX" or the "Company") (TSX VENTURE:MDX) announces that it
has closed on a first tranche of a private placement, as previously announced on
January 22, 2014. Trapeze Capital Corp., acted as lead agent (the "Agent"), to
raise gross proceeds of up to $2.0 million, from accredited investors, on a
reasonable efforts basis through a private placement of Units. The first tranche
which was closed today, raised gross proceeds of $565,000 to its treasury by
issuance of 5,650,000 units, comprising 5,650,000 common shares and 5,650,000
share purchase warrants ("Warrants") at $0.10 per unit. Each Warrant entitles
the holder to purchase one additional common share during the period expiring
March 19, 2016, at $0.20 per share. The securities issued through the private
placement were subscribed for by accredited investors, and are restricted from
trading before July 20, 2014. At closing, MedX paid the Agent a cash commission
of $24,200, and issued 452,000 broker warrants to the Agent. Each broker warrant
will be exercisable at $0.10 to acquire a unit comprising one common share and
one share purchase warrant exercisable to acquire an additional common share
from treasury at an exercise price of $0.20; the broker warrants and the share
purchase warrants underlying the broker warrants will expire on March 19, 2016.
Any shares issued on exercise of the broker warrants or the share purchase
warrants underlying the units in the broker warrants will be restricted from
trading until July 20, 2014. 


MedX intends to close on a further tranche of this private placement. 

Following the foregoing issuance of shares in the placement, MedX has 65,394,657
shares outstanding.


About MedX 

MedX is headquartered in Mississauga, Ontario (Toronto), and is a global leader
in the design, manufacturing and distribution of quality low level laser and
light therapy technologies for use in numerous medical settings, including
rehab/chiropractic, dental, wound care, and veterinary medicine, providing
patients with drug free and non-invasive treatment of tissue damage and pain.
MedX laser and light products are FDA approved, Health Canada cleared, and CE
Mark approved for use in North America as well as the European Union. MedX's
products include SIMSYS(TM) and MoleMate(TM), which are approved by Health
Canada, and available to Canadian physicians and dermatologists, are FDA
approved for use in the USA and are currently under review for CE approval for
use in Europe, the UK, and Australia, as an optical biopsy that uses patented
technology featuring a hand-held scanner device designed for clinical use that
utilizes light to view beneath suspicious moles or lesions in a pain free,
non-invasive manner, creating images in real-time for physicians and
dermatologists to evaluate all types of moles or lesions within seconds. For
more information log onto: www.simsys-molemate.com. For a complete profile of
MedX and its products visit www.medxhealth.com. 


This press release does not constitute an offer of any securities for sale. This
press release contains certain forward-looking statements within the meaning of
applicable Canadian securities legislation. These forward-looking statements
involve certain risks and uncertainties that could cause actual results to
differ, including, without limitation, the company's limited operating history
and history of losses, the inability to successfully obtain further funding, the
inability to raise capital on terms acceptable to the company, the inability to
compete effectively in the marketplace, the inability to complete the proposed
acquisition and such other risks that could cause the actual results to differ
materially from those contained in the company's projections or forward-looking
statements. All forward looking statements in this press release are based on
information available to the company as of the date hereof, and the company
undertakes no obligation to update forward-looking statements to reflect events
or circumstances occurring after the date of this press release.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this press release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
MedX Health Corp.
Robert von der Porten
President and CEO
905 670 4428
investor@medxhealth.com
Medx Health (TSXV:MDX)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024